TRANSFIX Zenith® Transection Clinical Study (TRANSFIX)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01688050 |
|
Recruitment Status :
Completed
First Posted : September 19, 2012
Results First Posted : November 18, 2015
Last Update Posted : November 18, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Thoracic Aorta Thoracic Injuries Blunt Injuries | Device: Zenith® TX2® Low Profile Endovascular Graft | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 50 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | TRANSFIX - Zenith® TX2® Low Profile Endovascular Graft for Blunt Thoracic Aortic Injury |
| Actual Study Start Date : | January 23, 2013 |
| Actual Primary Completion Date : | June 2014 |
| Actual Study Completion Date : | July 29, 2019 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Endovascular Repair |
Device: Zenith® TX2® Low Profile Endovascular Graft
Treatment of Blunt thoracic aortic injuries (BTAIs)
Other Name: Zenith Alpha Thoracic™ Endovascular Graft |
- All-cause Mortality [ Time Frame: 30 days ]
- Aortic Injury-related Mortality [ Time Frame: 30 days ]Any death determined by the independent clinical events committee to be causally related to the initial implant procedure, secondary intervention, or rupture of the transected aorta.
- Device Success [ Time Frame: 30 days ]Technical success (successful access, deployment, and patency of the Zenith® TX2® Low Profile Endovascular Graft), and freedom from the following: device collapse, type I or type III endoleaks requiring reintervention, and conversion to open surgical repair.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Vessels suitable for endovascular access and stent graft placement
- Blunt thoracic aortic injury of the descending thoracic aorta
- At least 16 years of age
- Informed consent given by patient or legally authorized representative
Exclusion Criteria:
- Clinical considerations that would compromise patient safety or study outcomes
- Unsuitable arterial anatomy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01688050
Show 21 study locations
| Principal Investigator: | Benjamin Starnes, MD | University of Washington - Harborview, Division of Vascular Surgery |
Documents provided by Cook Group Incorporated ( Cook Research Incorporated ):
| Responsible Party: | Cook Research Incorporated |
| ClinicalTrials.gov Identifier: | NCT01688050 |
| Other Study ID Numbers: |
11-004 |
| First Posted: | September 19, 2012 Key Record Dates |
| Results First Posted: | November 18, 2015 |
| Last Update Posted: | November 18, 2020 |
| Last Verified: | October 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
|
Blunt thoracic aortic injury Transection Endovascular graft |
|
Aneurysm, Dissecting Wounds and Injuries Thoracic Injuries Wounds, Nonpenetrating |
Aneurysm Vascular Diseases Cardiovascular Diseases |

